FDA Approves Brytly, a Nonprescription Apraclonidine Eye Drop for Eye Redness
Publication date: October 16, 2026
Source: Primary Care Optometry News
Product: Brytly (apraclonidine ophthalmic solution, 0.125%)
Manufacturer: Alcon
1-Minute Summary
The US Food and Drug Administration (FDA) has approved Brytly, a nonprescription ophthalmic solution containing apraclonidine 0.125%, for temporary relief of eye redness associated with minor irritations. According to the report, the product is approved for individuals aged 12 years and older.
The recommended use described in the report is no more than twice daily. Contact lenses should be removed before administration, with users waiting at least 10 minutes after applying the drops before reinserting them. People using other ophthalmic medications should wait 5 minutes between Brytly and another eye drop.
The FDA said the approval aligns with its public health priorities, including improving access to affordable medicines and medical products. Mike Davis, MD, PhD, director of the FDA Center for Drug Evaluation and Research, described the approval as providing consumers with another convenient nonprescription option for managing eye redness.
The supplied report does not include clinical trial results, comparative efficacy data, the full safety profile, or a prescribing-information link. Consumers should follow the product’s approved labeling and seek professional assessment when redness is persistent, severe, recurrent, or accompanied by pain or visual changes.
Why This Matters
Eye redness is a common symptom that can occur with minor irritation, but it can also accompany conditions requiring medical evaluation. A nonprescription treatment option may make symptom management more accessible for eligible consumers.
The approval is also relevant to optometrists, ophthalmologists, pharmacists, and primary care clinicians who counsel patients about over-the-counter eye products. Clear instructions on age eligibility, dosing frequency, contact lens use, and spacing between eye drops can help patients use products appropriately.
However, the approval announcement alone does not establish how Brytly compares with other redness-relieving products, how quickly it works, how long its effects last, or which patients may be at greater risk of adverse effects. Those questions require information from the approved labeling and supporting clinical evidence.
Regulatory Update at a Glance
| Feature | Details |
|---|---|
| Update type | FDA regulatory approval announcement |
| Product | Brytly |
| Active ingredient | Apraclonidine |
| Formulation | Ophthalmic solution, 0.125% |
| Manufacturer | Alcon |
| Indication reported | Relief of eye redness associated with minor irritations |
| Prescription status | Nonprescription |
| Approved age group | Individuals aged 12 years and older |
| Maximum frequency stated in the report | No more than twice daily |
| Contact lens instruction | Remove lenses before use; wait at least 10 minutes before reinsertion |
| Spacing from other eye drops | Wait 5 minutes before applying other ophthalmic drops |
| Comparator | Not applicable to this regulatory news report |
| Study participants | Not reported |
| Clinical trial outcomes | Not reported |
| Follow-up | Not reported |
| FDA rationale highlighted | Expanded access to safe and effective nonprescription treatments |
| Original research / DOI | Not supplied in the report |
What the FDA and Company Announcement Reported
Approval for nonprescription use
The FDA approved Brytly as a nonprescription eye drop intended to relieve redness associated with minor irritations. The product contains apraclonidine ophthalmic solution at a concentration of 0.125% and is approved for people aged 12 years and older, according to the report.
The announcement does not provide detailed clinical efficacy results, a comparison with other over-the-counter redness-relieving products, or the full list of contraindications and warnings. These details should be checked in the official product labeling.
Dosing and administration instructions
Report states that Brytly should be used no more than twice per day. It also provides instructions for contact lens users and people applying more than one ophthalmic medication.
| Use consideration | Instruction reported |
|---|---|
| Age | 12 years and older |
| Frequency | No more than twice daily |
| Contact lenses | Remove before applying the drops |
| Reinserting contact lenses | Wait at least 10 minutes after administration |
| Other eye drops | Wait 5 minutes before applying another ophthalmic product |
These are the instructions reported in the supplied news article. Users should check the final package labeling for the complete directions, precautions, and any additional restrictions.
FDA public health priorities
The FDA linked the approval to its broader public health priorities, including โincreasing access to affordable medicines and medical products.โ
Mike Davis, MD, PhD, director of the FDA Center for Drug Evaluation and Research, stated:
โExpanding access to safe and effective nonprescription treatments is a priority for FDA.โ
He added:
โTodayโs approval of Brytly gives consumers a new nonprescription option to manage eye redness conveniently and without needing to see a healthcare provider.โ
The statements describe the FDA’s rationale for expanding access to nonprescription treatment. They do not, by themselves, provide comparative clinical evidence or quantify the product’s effectiveness.
Clinical Significance
The approval introduces another nonprescription option for eligible people seeking relief from eye redness associated with minor irritation. Its practical value will depend on the product’s demonstrated efficacy, safety, duration of action, labeling instructions, and suitability for individual users.
Clinicians should distinguish uncomplicated redness from symptoms that could indicate a more serious ocular condition. Eye redness accompanied by significant pain, light sensitivity, reduced or blurred vision, injury, marked discharge, or a painful red eye in a contact lens wearer warrants prompt clinical assessment rather than reliance on self-treatment alone.
The supplied announcement does not provide enough information to determine whether Brytly is more effective or safer than alternative products, or to identify the patients most likely to benefit.
What Doctors and Pharmacists Should Know
- Confirm age eligibility: The report states that Brytly is approved for people aged 12 years and older.
- Explain the reported dosing limit: Use should not exceed twice daily, according to the supplied report. Patients should follow the complete package instructions.
- Review contact lens precautions: Lenses should be removed before use, with at least 10 minutes allowed before reinsertion.
- Discuss spacing between ophthalmic products: The report advises waiting 5 minutes before applying other eye drops.
- Assess the cause of redness: Redness may reflect minor irritation, but it can also be a sign of infection, inflammation, corneal injury, or other ocular disease.
- Avoid unsupported comparisons: The announcement does not provide evidence that Brytly is superior to other redness-relieving products.
- Consult the approved labeling: Verify the full warnings, contraindications, adverse reactions, and instructions before providing product-specific counseling.
Limitations of the Available Report
This is a brief regulatory news report, not a full clinical study or a comprehensive review of the product’s evidence.
- No clinical trial data: The article does not report the number of participants, trial design, efficacy outcomes, or statistical analyses supporting approval.
- No comparative results: The report does not compare Brytly with placebo or other redness-relieving treatments.
- Incomplete safety information: Although dosing instructions are provided, the supplied article does not detail adverse reactions, contraindications, interactions, or special-population precautions.
- Developing news: The source explicitly identifies the report as a developing story and advises readers to check back for updates.
- No original research citation or DOI: The supplied report does not identify a clinical publication or provide a DOI.
These limitations mean that the approval can be described, but detailed claims about efficacy, duration of action, or comparative safety should not be made without additional source documentation.
Original Research / DOI
Original research: Not identified in the supplied news report.
DOI: Not provided.
Evidence classification: FDA regulatory approval announcement. The report does not provide enough information to classify the underlying supporting evidence as a randomized controlled trial, cohort study, or meta-analysis.
Bottom Line
The FDA approved Brytly (apraclonidine ophthalmic solution, 0.125%) as a nonprescription option for relief of eye redness associated with minor irritations in people aged 12 years and older. The supplied report states that it should be used no more than twice daily, with contact lenses removed before use and specific waiting periods observed before reinsertion or use of other eye drops.
The approval expands reported nonprescription options for eye redness, but the news article does not provide clinical trial results or a complete safety profile. Patients and clinicians should consult the official product labeling and ensure that persistent or concerning eye symptoms receive appropriate evaluation.